Two board appointments at Pulmatrix
This article was originally published in Scrip
Executive Summary
Pulmatrix (US), a clinical-stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, has appointed Kurt Graves and David Maki to its board of directors. Mr Graves has more than 20 years' management experience in US and European pharmaceutical and biotech companies, having most recently served as executive vice-president, chief commercial officer and head of corporate and strategic development at Vertex Pharmaceuticals. Mr Maki co-founded Altitude Life Science Ventures, and previously served as a principal with Perennial Ventures and as a vice-president with Tredegar Investments.